Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells

Review the clinical trials studying allogeneic pd-l1 tumor-targeted high-affinity natural killer cells on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-2 of 2

PD-L1 t-haNK with N-803 and Cetuximab for the Treatment of Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland